title: [Clinical and Prognostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin in Patients With ST-Segment Elevation Myocardial Infarction].
abstract: OBJECTIVE
  to study clinical and prognostic significance of serum neutrophil gelatinase-associated lipocalin (s-NGAL) in patients with ST-segment elevation myocardial infarction (STEMI).
  
  
  METHODS
  Patients with STEMI (n=85) of less than 24 hours duration admitted to the Kemerovo Cardiology Dispensary were included in the study. s-NGAL levels (ng/ml) were measured on day 1 and 12 of hospital stay by ELISA using commercial kit. Reinfarction rate and mortality were assessed over 3-year follow-up.
  
  
  RESULTS
  Median s-NGAL levels on day1 and 12 were 1.33 (0.36-1.90) and 1.63 (1.25-2.61) ng/ml, that corresponded to a 3.32- and 4.07-fold increase, respectively, compared to reference values. Between days 1 and 12 s-NGAL levels increased by 22.55 % (p=0.0009). Higher values of serum NGAL on day 12 of MI were associated with presence of renal structural lesions, three-vessel coronary artery disease and anterior MI. Patients who underwent percutaneous coronary intervention (PCI) demonstrated only a negligible increase of s-NGAL level by day 12 while in those not subjected to PCI 3-fold increase was observed. Patients with s-NGAL levels >2.6 ng/ml compared with other patients had higher mortality (9.52 vs 31.83%; odds ratio 4.42 [1.30-15.16], p=0.012).
  
  
  CONCLUSIONS
  High values of serum NGAL in STEMI patients were associated with severe clinical status. s-NGAL level above 2.6 ng/ml on day 12 of hospital stay was associated with 4- fold increase of all-cause mortality during 3-year follow-up.
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: M V
authors.initials: MV
authors.lastname: Zykov
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Kashtalap
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: I S
authors.initials: IS
authors.lastname: Bykova
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: O N
authors.initials: ON
authors.lastname: Hryachkova
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Kalaeva
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: K S
authors.initials: KS
authors.lastname: Shafranskaya
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: V N
authors.initials: VN
authors.lastname: Karetnikova
authors.affiliation: 1Institute for Complex Problems of ardiovascular Disease; 2State Medical Academy of the Ministry of Health, Kemerovo, Russia.
authors.forename: O L
authors.initials: OL
authors.lastname: Barbarash
mesh_terms: D000209:Acute-Phase Proteins; D015415:Biomarkers; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins; D009203:Myocardial Infarction; D011379:Prognosis; D011518:Proto-Oncogene Proteins
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins